|
|
|
Originator Org.- |
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date01 Jan 1947 |
|
|
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
[Translation] PK study of lidocaine patch 5% in healthy Chinese subjects
主要目的:评估利多卡因贴片5%单剂和多剂给药后在中国健康受试者中利多卡因的药代动力学(PK)特征及其系统暴露情况
次要目的:评估利多卡因贴片5%的安全性和耐受性
[Translation] Primary objective: To evaluate the pharmacokinetic (PK) characteristics and systemic exposure of lidocaine in Chinese healthy subjects after single and multiple doses of lidocaine patch 5%
Secondary objective: To evaluate the safety and tolerability of lidocaine patch 5%
一项在带状疱疹相关疼痛 (HZAP)受试者中对利多卡因贴片5%与安慰剂的疗效和安全性进行比较的双盲研究
[Translation] A Double-Blind Study Comparing the Efficacy and Safety of Lidocaine Patch 5% with Placebo in Subjects with Herpes Zoster-Associated Pain (HZAP)
一项在带状疱疹相关疼痛 (HZAP)受试者中对利多卡因贴片5%与安慰剂的疗效和安全性进行比较的双盲研究
[Translation] A Double-Blind Study Comparing the Efficacy and Safety of Lidocaine Patch 5% with Placebo in Subjects with Herpes Zoster-Associated Pain (HZAP)
100 Clinical Results associated with China Center for Pharmaceutical International Exchange (CCPIE)
0 Patents (Medical) associated with China Center for Pharmaceutical International Exchange (CCPIE)
100 Deals associated with China Center for Pharmaceutical International Exchange (CCPIE)
100 Translational Medicine associated with China Center for Pharmaceutical International Exchange (CCPIE)